Search Results Search Sort by RelevanceMost Recent Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Health Law Dec 2004 What Counts as Expert Medical Testimony? Mollie E. O'Brien Medical standards of care and legal standards of reliability and relevance sometimes conflict in courtroom settings. Virtual Mentor. 2004;6(12):554-557. doi: 10.1001/virtualmentor.2004.6.12.hlaw1-0412. State of the Art and Science Jun 2005 Recognition and Treatment of Depression Holly A. Swartz, MD A physician outlines the criteria for diagnosing clinical depression and the principle modes for treating the mental illness. Virtual Mentor. 2005;7(6):430-434. doi: 10.1001/virtualmentor.2005.7.6.cprl1-0506. Viewpoint Nov 2005 Steroid Hysteria: Unpacking the Claims Norman Fost, MD, MPH A physician argues in favor of the use of performance-enhancing substances by adult participants in sports. Virtual Mentor. 2005;7(11):767-769. doi: 10.1001/virtualmentor.2005.7.11.oped2-0511. Viewpoint Nov 2005 Medical Ethics and Performance-Enhancing Drugs Carlos R. Hamilton, MD A physician's role in controlling the abuse of performance-enhancing drugs includes educating patients about the harms associated with these drugs and encouraging them to adopt safe and appropriate training programs. Virtual Mentor. 2005;7(11):764-766. doi: 10.1001/virtualmentor.2005.7.11.oped1-0511. Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408. In the Literature Aug 2004 Ethical Issues in the Application and Prescription of CNS Interventions Abraham P. Schwab, PhD A neuroscientist and a sociologist discuss the ethical concerns with common neurological medicines that are used to enhance or change behavior. Virtual Mentor. 2004;6(8):347-349. doi: 10.1001/virtualmentor.2004.6.8.jdsc1-0408. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. In the Literature Nov 2004 Maintaining Integrity in Industry-Sponsored Research Alison Bickford Many ethical and legal issues arise when academic medical research is sponsored by pharmaceutical companies. Virtual Mentor. 2004;6(11):490-493. doi: 10.1001/virtualmentor.2004.6.11.jdsc2-0411. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. Pagination First page « First Previous page ‹ Previous … Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Current page 23 Page 24 Next page Next › Last page Last »
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Health Law Dec 2004 What Counts as Expert Medical Testimony? Mollie E. O'Brien Medical standards of care and legal standards of reliability and relevance sometimes conflict in courtroom settings. Virtual Mentor. 2004;6(12):554-557. doi: 10.1001/virtualmentor.2004.6.12.hlaw1-0412.
State of the Art and Science Jun 2005 Recognition and Treatment of Depression Holly A. Swartz, MD A physician outlines the criteria for diagnosing clinical depression and the principle modes for treating the mental illness. Virtual Mentor. 2005;7(6):430-434. doi: 10.1001/virtualmentor.2005.7.6.cprl1-0506.
Viewpoint Nov 2005 Steroid Hysteria: Unpacking the Claims Norman Fost, MD, MPH A physician argues in favor of the use of performance-enhancing substances by adult participants in sports. Virtual Mentor. 2005;7(11):767-769. doi: 10.1001/virtualmentor.2005.7.11.oped2-0511.
Viewpoint Nov 2005 Medical Ethics and Performance-Enhancing Drugs Carlos R. Hamilton, MD A physician's role in controlling the abuse of performance-enhancing drugs includes educating patients about the harms associated with these drugs and encouraging them to adopt safe and appropriate training programs. Virtual Mentor. 2005;7(11):764-766. doi: 10.1001/virtualmentor.2005.7.11.oped1-0511.
Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408.
In the Literature Aug 2004 Ethical Issues in the Application and Prescription of CNS Interventions Abraham P. Schwab, PhD A neuroscientist and a sociologist discuss the ethical concerns with common neurological medicines that are used to enhance or change behavior. Virtual Mentor. 2004;6(8):347-349. doi: 10.1001/virtualmentor.2004.6.8.jdsc1-0408.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.
In the Literature Nov 2004 Maintaining Integrity in Industry-Sponsored Research Alison Bickford Many ethical and legal issues arise when academic medical research is sponsored by pharmaceutical companies. Virtual Mentor. 2004;6(11):490-493. doi: 10.1001/virtualmentor.2004.6.11.jdsc2-0411.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.